Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Follow-Up Questions
Biogen Inc (BIIB)의 PER은 얼마입니까?
Biogen Inc의 PER은 12.9173입니다
Biogen Inc의 CEO는 누구입니까?
Mr. Christopher Viehbacher은 2022부터 회사에 합류한 Biogen Inc의 President입니다.
BIIB 주식의 가격 성능은 어떻습니까?
BIIB의 현재 가격은 $147.97이며, 전 거래일에 decreased 0.9% 하였습니다.
Biogen Inc의 주요 사업 주제나 업종은 무엇입니까?
Biogen Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Biogen Inc의 시가총액은 얼마입니까?
Biogen Inc의 현재 시가총액은 $21.6B입니다
Biogen Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 33명의 분석가가 Biogen Inc에 대한 분석 평가를 실시했으며, 이는 7명의 강력한 매수, 14명의 매수, 20명의 보유, 1명의 매도, 그리고 7명의 강력한 매도를 포함합니다
